Sasanlimab (PF-06801591, PD-1 Inhibitor) in Participants With Advanced Malignancies

Study Summary

This is a Phase 1b/2 protocol to evaluate pharmacokinetics, safety, efficacy, and pharmacodynamics of PF-06801591, a programmed death-1(PD-1) antagonist monoclonal antibody (mAb) in participants with advanced malignancies. This study consists of 2 parts: Phase 1b part (dose escalation and dose expansion) in patients with advanced malignancies in Asia and a global Phase 2 part in non small cell lung cancer (NSCLC) patients.

Conditions

Advanced Malignancies Non-small-cell Lung Cancer

Interventions / Drugs

PF-06801591

View on ClinicalTrials.gov ↗

Sponsor

Study Details

Enrollment155 participants

Primary Completion—

Lead SponsorPfizer

Data Retrieved2026-04-11 02:55:53.191074+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.